Acute Coronary Syndrome News and Research

RSS

Study: More PCIs classified as appropriate for acute indications in the U.S.

In an examination of the appropriateness of the widespread use of percutaneous coronary interventions (PCIs), researchers found that of more than 500,000 PCIs included in the study, nearly all for acute indications were classified as appropriate, whereas only about half of PCIs performed for nonacute indications could be classified as appropriate, according to a study in the July 6 issue of JAMA.

6 Jul 2011

New clot busting drug approved in UK

The National Institute for Clinical Excellence (Nice), UK, has approved a new drug which one study has suggested could reduce the risk of death from a second heart attack by 20 per cent. The drug is manufactured by AstraZeneca as Brilique. It works by maintaining cardiac blood flow and stopping new blood clots from forming.

1 Jul 2011

ESC Congress 2011 to spotlight 'controversial issues in cardiology'

The scientific programme for this year's ESC Congress, which will take place in Paris from 27-31 August, is now complete and promises to provide journalists with a rich source of front-page news stories and background for topical features.

30 Jun 2011

Ticagrelor drug with low-dose aspirin effective against acute coronary syndrome

When taken with higher doses of aspirin, the experimental antiplatelet drug ticagrelor was associated with worse outcomes than the standard drug, clopidogrel, but the opposite was true with lower doses of aspirin.

28 Jun 2011

Randox launches automated laboratory assay for Heart-type Fatty Acid Binding Protein

Randox Laboratories, the international clinical diagnostics company, has today launched an automated laboratory assay for Heart-type Fatty Acid Binding Protein (H-FABP), to improve the diagnosis and management of patients with suspected acute coronary syndrome (ACS).

From Randox Laboratories Ltd. 20 Jun 2011

Cholesterol-lowering statins reduce rate of mortality and cardiovascular events

Over the long term, treatment with cholesterol-lowering statins reduces the rate of mortality and cardiovascular events such as heart attack, for people with and without heart disease. Still, it is unclear whether these drugs take effect rapidly when the risk of these dire events is highest.

15 Jun 2011

New drug more effective than standard treatment to prevent heart-attack deaths

Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor, was used instead of the standard treatment, clopidogrel.

13 Jun 2011

Researchers explore relationship between emotions and poor prognosis in heart disease

Intense distress and fear of dying, which many people experience when suffering the symptoms of a heart attack, are not only fairly common emotional responses but are also linked to biological changes that occur during the event, according to new research published online today in the European Heart Journal.

2 Jun 2011

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke.

27 May 2011

Study explores link between specific temperament traits and clinical events after heart attack

This study explores for the first time the potential predictive power of Cloninger's temperament traits on prognosis in patients after an acute coronary syndrome admission.

19 May 2011

Sensitive troponin assays improve clinical outcome and cardiac patient management

Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower diagnostic threshold for troponin improves clinical outcomes and patient survival in patients with suspected acute coronary syndromes.

19 May 2011

Workplace smoking ban improves respiratory health and reduces emergency admissions

Workplace smoking bans are gaining ground globally, and one study has shown that they may have significant health effects. The study, conducted by researchers in Dublin, found that emergency room admissions due to respiratory illness dropped significantly in Ireland after the implementation of a workplace smoking ban, compared to admissions that took place before the ban went into effect.

18 May 2011

UCSF nursing professor earns AACN-GE recognition for cardiac care

RN, PhD, FAAN, Lillian & Dudley Aldous Professor of Nursing Science, School of Nursing, University of California San Francisco — will receive the AACN-GE Healthcare Pioneering Spirit Award.

30 Apr 2011

Study finds increase in implementation of evidence-based therapies for myocardial infarction

In an analysis of data from a coronary care registry in Sweden, between 1996-2007 there was an increase in the prevalence of use of evidence-based invasive procedures and pharmacological therapies for treatment of a certain type of heart attack, and a decrease in the rate of death at 30 days and one year after a heart attack for these patients, according to a study in the April 27 issue of JAMA.

28 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

Both radial and femoral approaches are safe and effective for angioplasty

In the future you may hear the doctor say: "Give me your arm and I'll do some heart surgery."

5 Apr 2011

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.

4 Apr 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

29 Mar 2011